Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised Heparin for COVID-19 (CHARTER-MT)
NCT04545541Phase 3Completed
- Sponsor
- Australian National University
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of heparin in coronavirus disease 2019 (COVID-19), sponsored by Australian National University. Started Nov 2020; status: completed.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04545541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545541.